-
1
-
-
84879880052
-
-
GLOBOCAN, cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer.
-
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer.
-
(2008)
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.M.6
-
2
-
-
36849065315
-
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
-
Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
-
(2007)
Cell
, vol.131
, pp. 1190-1203
-
-
Rikova, K.1
Guo, A.2
Zeng, Q.3
Possemato, A.4
Yu, J.5
Haack, H.6
-
3
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
-
(2007)
Nature
, vol.448
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
Takada, S.4
Yamashita, Y.5
Ishikawa, S.6
-
4
-
-
0042030813
-
Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)
-
Ouyang T., Bai R.Y., Bassermann F., von Klitzing C., Klumpen S., Miething C., et al. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J Biol Chem 2003, 278:30028-30036.
-
(2003)
J Biol Chem
, vol.278
, pp. 30028-30036
-
-
Ouyang, T.1
Bai, R.Y.2
Bassermann, F.3
von Klitzing, C.4
Klumpen, S.5
Miething, C.6
-
5
-
-
2342635959
-
Anaplastic lymphoma kinase proteins in growth control and cancer
-
Pulford K., Morris S.W., Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004, 199:330-358.
-
(2004)
J Cell Physiol
, vol.199
, pp. 330-358
-
-
Pulford, K.1
Morris, S.W.2
Turturro, F.3
-
6
-
-
77956200561
-
Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth
-
Riera L., Lasorsa E., Ambrogio C., Surrenti N., Voena C., Chiarle R. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem 2010, 285:26441-26450.
-
(2010)
J Biol Chem
, vol.285
, pp. 26441-26450
-
-
Riera, L.1
Lasorsa, E.2
Ambrogio, C.3
Surrenti, N.4
Voena, C.5
Chiarle, R.6
-
7
-
-
57349113565
-
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
-
Takeuchi K., Choi Y.L., Soda M., Inamura K., Togashi Y., Hatano S., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008, 14:6618-6624.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6618-6624
-
-
Takeuchi, K.1
Choi, Y.L.2
Soda, M.3
Inamura, K.4
Togashi, Y.5
Hatano, S.6
-
8
-
-
63949086127
-
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer
-
Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3143-3149
-
-
Takeuchi, K.1
Choi, Y.L.2
Togashi, Y.3
Soda, M.4
Hatano, S.5
Inamura, K.6
-
9
-
-
84869462031
-
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology
-
Ou S.H., Bartlett C.H., Mino-Kenudson M., Cui J., Iafrate A.J. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012, 17:1351-1375.
-
(2012)
Oncologist
, vol.17
, pp. 1351-1375
-
-
Ou, S.H.1
Bartlett, C.H.2
Mino-Kenudson, M.3
Cui, J.4
Iafrate, A.J.5
-
10
-
-
84856893071
-
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer
-
Tiseo M., Gelsomino F., Bartolotti M., Bordi P., Bersanelli M., Rossi G., et al. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 2011, 11:1677-1687.
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, pp. 1677-1687
-
-
Tiseo, M.1
Gelsomino, F.2
Bartolotti, M.3
Bordi, P.4
Bersanelli, M.5
Rossi, G.6
-
11
-
-
74249123333
-
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer
-
Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009, 4:1450-1454.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1450-1454
-
-
Solomon, B.1
Varella-Garcia, M.2
Camidge, D.R.3
-
12
-
-
70349336416
-
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
-
Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4247-4253
-
-
Shaw, A.T.1
Yeap, B.Y.2
Mino-Kenudson, M.3
Digumarthy, S.R.4
Costa, D.B.5
Heist, R.S.6
-
13
-
-
84856236043
-
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbour EGFR or KRAS mutations or ALK rearrangement
-
Kim H.R., Shim H.S., Chung J.H., Lee Y.J., Hong Y.K., Rha S.Y., et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbour EGFR or KRAS mutations or ALK rearrangement. Cancer 2012, 118:729-739.
-
(2012)
Cancer
, vol.118
, pp. 729-739
-
-
Kim, H.R.1
Shim, H.S.2
Chung, J.H.3
Lee, Y.J.4
Hong, Y.K.5
Rha, S.Y.6
-
14
-
-
84879886060
-
-
Pfizer Inc. Xalkori Prescribing Information. US Food and Drug Administration.
-
Pfizer Inc. Xalkori Prescribing Information. US Food and Drug Administration.
-
-
-
-
15
-
-
37549059613
-
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
-
Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 3314-3322
-
-
Christensen, J.G.1
Zou, H.Y.2
Arango, M.E.3
Li, Q.4
Lee, J.H.5
McDonnell, S.R.6
-
16
-
-
34249324494
-
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
-
Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67:4408-4417.
-
(2007)
Cancer Res
, vol.67
, pp. 4408-4417
-
-
Zou, H.Y.1
Li, Q.2
Lee, J.H.3
Arango, M.E.4
McDonnell, S.R.5
Yamazaki, S.6
-
17
-
-
78650974101
-
Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors
-
Li Y., Ye X., Liu J., Zha J., Pei L. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 2011, 13:1-11.
-
(2011)
Neoplasia
, vol.13
, pp. 1-11
-
-
Li, Y.1
Ye, X.2
Liu, J.3
Zha, J.4
Pei, L.5
-
18
-
-
44849126091
-
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
-
McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-3395.
-
(2008)
Cancer Res
, vol.68
, pp. 3389-3395
-
-
McDermott, U.1
Iafrate, A.J.2
Gray, N.S.3
Shioda, T.4
Classon, M.5
Maheswaran, S.6
-
19
-
-
79952773320
-
Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients
-
Abstr. 2596
-
Tan W., Wilner K.D., Bang Y., Kwak E.L., Maki R.G., Camidge D.R., et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J Clin Oncol 2010, 28(Suppl.). Abstr. 2596.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Tan, W.1
Wilner, K.D.2
Bang, Y.3
Kwak, E.L.4
Maki, R.G.5
Camidge, D.R.6
-
20
-
-
80052492099
-
Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC)
-
Abstr. 2501
-
Camidge D.R., Bang Y., Kwak E.L., Shaw A.T., Iafrate A.J., Maki R.G., et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.). Abstr. 2501.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Camidge, D.R.1
Bang, Y.2
Kwak, E.L.3
Shaw, A.T.4
Iafrate, A.J.5
Maki, R.G.6
-
21
-
-
84865431278
-
Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)
-
Abstr. 7533
-
Kim D.-W., Ahn M.-J., Shi Y., Martino De Pas T., Yang P.-C., Riely G.J., et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012, 30(Suppl.). Abstr. 7533.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Kim, D.-W.1
Ahn, M.-J.2
Shi, Y.3
Martino De Pas, T.4
Yang, P.-C.5
Riely, G.J.6
-
22
-
-
84872569905
-
Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007)
-
Abstr. 2862
-
Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinò L., Ahn M.-J., et al. Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007). Ann Oncol 2012, 23(Suppl. 9). Abstr. 2862.
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL. 9
-
-
Shaw, A.T.1
Kim, D.W.2
Nakagawa, K.3
Seto, T.4
Crinò, L.5
Ahn, M.-J.6
-
23
-
-
84878348199
-
Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib
-
Abstr. 7596
-
Salgia R., Solomon B.J., Shaw A.T., Camidge D.R., Evans T.L., Kim D.-W., et al. Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib. J Clin Oncol 2012, 30(Suppl.). Abstr. 7596.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Salgia, R.1
Solomon, B.J.2
Shaw, A.T.3
Camidge, D.R.4
Evans, T.L.5
Kim, D.-W.6
-
24
-
-
84859124139
-
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
-
Ou S.H. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011, 5:471-485.
-
(2011)
Drug Des Devel Ther
, vol.5
, pp. 471-485
-
-
Ou, S.H.1
-
25
-
-
78049426513
-
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
-
Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739.
-
(2010)
N Engl J Med
, vol.363
, pp. 1734-1739
-
-
Choi, Y.L.1
Soda, M.2
Yamashita, Y.3
Ueno, T.4
Takashima, J.5
Nakajima, T.6
-
26
-
-
80052793410
-
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
-
Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71:6051-6060.
-
(2011)
Cancer Res
, vol.71
, pp. 6051-6060
-
-
Sasaki, T.1
Koivunen, J.2
Ogino, A.3
Yanagita, M.4
Nikiforow, S.5
Zheng, W.6
-
27
-
-
84856990335
-
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
-
Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1472-1482
-
-
Doebele, R.C.1
Pilling, A.B.2
Aisner, D.L.3
Kutateladze, T.G.4
Le, A.T.5
Weickhardt, A.J.6
-
28
-
-
82555205478
-
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
-
Heuckmann J.M., Holzel M., Sos M.L., Heynck S., Balke-Want H., Koker M., et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011, 17:7394-7401.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 7394-7401
-
-
Heuckmann, J.M.1
Holzel, M.2
Sos, M.L.3
Heynck, S.4
Balke-Want, H.5
Koker, M.6
-
29
-
-
84856999699
-
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
-
Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra17.
-
(2012)
Sci Transl Med
, vol.4
-
-
Katayama, R.1
Shaw, A.T.2
Khan, T.M.3
Mino-Kenudson, M.4
Solomon, B.J.5
Halmos, B.6
-
30
-
-
84866773924
-
Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients
-
Abstr. 7504
-
Doebele R.C., Aisner D.L., Le A.T., Berge E.M., Pilling A.B., Kutateladze T.G., et al. Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. J Clin Oncol 2012, 30(Suppl.). Abstr. 7504.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Doebele, R.C.1
Aisner, D.L.2
Le, A.T.3
Berge, E.M.4
Pilling, A.B.5
Kutateladze, T.G.6
-
31
-
-
79955964568
-
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
-
Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami T.A., et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.
-
(2011)
Cancer Cell
, vol.19
, pp. 679-690
-
-
Sakamoto, H.1
Tsukaguchi, T.2
Hiroshima, S.3
Kodama, T.4
Kobayashi, T.5
Fukami, T.A.6
-
32
-
-
79956318797
-
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
-
Katayama R., Khan T.M., Benes C., Lifshits E., Ebi H., Rivera V.M., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011, 108:7535-7540.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 7535-7540
-
-
Katayama, R.1
Khan, T.M.2
Benes, C.3
Lifshits, E.4
Ebi, H.5
Rivera, V.M.6
-
33
-
-
84875948814
-
AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC
-
Abstract 1794
-
Rivera V.M., Wang F., Anjum R., Zhang S., Squillace R., Keats J., et al. AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012, Abstract 1794.
-
(2012)
Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research
-
-
Rivera, V.M.1
Wang, F.2
Anjum, R.3
Zhang, S.4
Squillace, R.5
Keats, J.6
-
34
-
-
84872304912
-
Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models
-
Abstr. A227
-
Kuromitsu S., Mori M., Shimada I., Kondoh Y., Shindoh N., Soga T., et al. Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models. Mol Cancer Ther 2011, 10(Suppl.). Abstr. A227.
-
(2011)
Mol Cancer Ther
, vol.10
, Issue.SUPPL.
-
-
Kuromitsu, S.1
Mori, M.2
Shimada, I.3
Kondoh, Y.4
Shindoh, N.5
Soga, T.6
-
35
-
-
84922680443
-
ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model
-
Abstract 866
-
Mori M., Kuromitsu S., Ueno Y., Tanaka R., Shimada I., Kondoh Y., et al. ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012, Abstract 866.
-
(2012)
Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research
-
-
Mori, M.1
Kuromitsu, S.2
Ueno, Y.3
Tanaka, R.4
Shimada, I.5
Kondoh, Y.6
-
36
-
-
84859400151
-
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers
-
Cheng M., Quail M.R., Gingrich D.E., Ott G.R., Lu L., Wan W. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 2012, 11:670-679.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 670-679
-
-
Cheng, M.1
Quail, M.R.2
Gingrich, D.E.3
Ott, G.R.4
Lu, L.5
Wan, W.6
-
37
-
-
84899592803
-
Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors
-
Lovly C.M., de Stanchina E., Chen H., Liang C., Pao W. Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors. J Clin Oncol 2011, 29(Suppl.):e13600.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Lovly, C.M.1
de Stanchina, E.2
Chen, H.3
Liang, C.4
Pao, W.5
-
38
-
-
84905173703
-
In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori
-
Abstract A232
-
Ardini E., Menichincheri M., Banfi P., Saccardo M.B., Rusconi L., Avanzi N., et al. In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. Mol Cancer Ther 2011, 10(Suppl.). Abstract A232.
-
(2011)
Mol Cancer Ther
, vol.10
, Issue.SUPPL.
-
-
Ardini, E.1
Menichincheri, M.2
Banfi, P.3
Saccardo, M.B.4
Rusconi, L.5
Avanzi, N.6
-
39
-
-
82555180241
-
An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC)
-
Abstr. 7500
-
Wong K., Koczywas M., Goldman J.W., Paschold E.H., Hom L., Lufkin J.M., et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.). Abstr. 7500.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Wong, K.1
Koczywas, M.2
Goldman, J.W.3
Paschold, E.H.4
Hom, L.5
Lufkin, J.M.6
-
40
-
-
78650363352
-
Association between anaplastic lymphoma kinase rearrangements (ALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC)
-
Abstr. 7517
-
Sequist L.V., Natale R.B., Senzer N.N., Martins R., Lilenbaum R., Gray J.E., et al. Association between anaplastic lymphoma kinase rearrangements (ALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(Suppl.). Abstr. 7517.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Sequist, L.V.1
Natale, R.B.2
Senzer, N.N.3
Martins, R.4
Lilenbaum, R.5
Gray, J.E.6
-
41
-
-
79956318148
-
Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer
-
Mino-Kenudson M., Mark E.J. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med 2011, 135:655-664.
-
(2011)
Arch Pathol Lab Med
, vol.135
, pp. 655-664
-
-
Mino-Kenudson, M.1
Mark, E.J.2
-
42
-
-
84873697461
-
Prevalence and clinical outcomes for patients with ALK positive adenocarcinoma in Europe: preliminary results from the European Thoracic Oncology Platform Lungscape Project
-
Abstr. 1670
-
Blackhall F.H., Peters S., Kerr K.M., O'Byrne K.J., Hager H., Sejda A., et al. Prevalence and clinical outcomes for patients with ALK positive adenocarcinoma in Europe: preliminary results from the European Thoracic Oncology Platform Lungscape Project. Ann Oncol 2012, 23(Suppl. 9). Abstr. 1670.
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL. 9
-
-
Blackhall, F.H.1
Peters, S.2
Kerr, K.M.3
O'Byrne, K.J.4
Hager, H.5
Sejda, A.6
-
43
-
-
79960240090
-
Case records of the Massachusetts General Hospital Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung
-
Shaw A.T., Forcione D.G., Digumarthy S.R., Iafrate A.J. Case records of the Massachusetts General Hospital Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. N Engl J Med 2011, 365:158-167.
-
(2011)
N Engl J Med
, vol.365
, pp. 158-167
-
-
Shaw, A.T.1
Forcione, D.G.2
Digumarthy, S.R.3
Iafrate, A.J.4
-
44
-
-
84870703622
-
Role of fluorescence in situ hybridization in lung cancer cytology
-
Savic S., Bubendorf L. Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 2012, 56:611-621.
-
(2012)
Acta Cytol
, vol.56
, pp. 611-621
-
-
Savic, S.1
Bubendorf, L.2
-
45
-
-
78349237453
-
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment
-
Camidge D.R., Kono S.A., Flacco A., Tan A.C., Doebele R.C., Zhou Q., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010, 16:5581-5590.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5581-5590
-
-
Camidge, D.R.1
Kono, S.A.2
Flacco, A.3
Tan, A.C.4
Doebele, R.C.5
Zhou, Q.6
-
47
-
-
77649091118
-
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
-
Mino-Kenudson M., Chirieac L.R., Law K., Hornick J.L., Lindeman N., Mark E.J., et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010, 16:1561-1571.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1561-1571
-
-
Mino-Kenudson, M.1
Chirieac, L.R.2
Law, K.3
Hornick, J.L.4
Lindeman, N.5
Mark, E.J.6
-
48
-
-
79951774364
-
Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH
-
Yi E.S., Boland J.M., Maleszewski J.J., Roden A.C., Oliveira A.M., Aubry M.C., et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011, 6:459-465.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 459-465
-
-
Yi, E.S.1
Boland, J.M.2
Maleszewski, J.J.3
Roden, A.C.4
Oliveira, A.M.5
Aubry, M.C.6
-
49
-
-
79951769488
-
Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization
-
Paik J.H., Choe G., Kim H., Choe J.Y., Lee H.J., Lee C.T., et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011, 6:466-472.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 466-472
-
-
Paik, J.H.1
Choe, G.2
Kim, H.3
Choe, J.Y.4
Lee, H.J.5
Lee, C.T.6
-
50
-
-
84857781304
-
Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study
-
McLeer-Florin A., Moro-Sibilot D., Melis A., Salameire D., Lefebvre C., Ceccaldi F., et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012, 7:348-354.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 348-354
-
-
McLeer-Florin, A.1
Moro-Sibilot, D.2
Melis, A.3
Salameire, D.4
Lefebvre, C.5
Ceccaldi, F.6
-
51
-
-
79955656623
-
Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer
-
Sanders H.R., Li H.R., Bruey J.M., Scheerle J.A., Meloni-Ehrig A.M., Kelly J.C., et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 2011, 204:45-52.
-
(2011)
Cancer Genet
, vol.204
, pp. 45-52
-
-
Sanders, H.R.1
Li, H.R.2
Bruey, J.M.3
Scheerle, J.A.4
Meloni-Ehrig, A.M.5
Kelly, J.C.6
-
52
-
-
84865743662
-
The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers
-
Wang R., Pan Y., Li C., Hu H., Zhang Y., Li H., et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012, 18:4725-4732.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4725-4732
-
-
Wang, R.1
Pan, Y.2
Li, C.3
Hu, H.4
Zhang, Y.5
Li, H.6
-
53
-
-
84856877692
-
The potential for crizotinib in non-small cell lung cancer: a perspective review
-
Bang Y.J. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol 2011, 3:279-291.
-
(2011)
Ther Adv Med Oncol
, vol.3
, pp. 279-291
-
-
Bang, Y.J.1
-
54
-
-
80051784751
-
Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression
-
Kim H., Yoo S.B., Choe J.Y., Paik J.H., Xu X., Nitta H., et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011, 6:1359-1366.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1359-1366
-
-
Kim, H.1
Yoo, S.B.2
Choe, J.Y.3
Paik, J.H.4
Xu, X.5
Nitta, H.6
-
55
-
-
80053043565
-
Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas
-
Yoshida A., Tsuta K., Nitta H., Hatanaka Y., Asamura H., Sekine I., et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011, 6:1677-1686.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1677-1686
-
-
Yoshida, A.1
Tsuta, K.2
Nitta, H.3
Hatanaka, Y.4
Asamura, H.5
Sekine, I.6
-
56
-
-
84862790522
-
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing
-
Jung Y., Kim P., Jung Y., Keum J., Kim S.N., Choi Y.S., et al. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 2012, 51:590-597.
-
(2012)
Genes Chromosomes Cancer
, vol.51
, pp. 590-597
-
-
Jung, Y.1
Kim, P.2
Jung, Y.3
Keum, J.4
Kim, S.N.5
Choi, Y.S.6
-
57
-
-
69349083935
-
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
-
Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5216-5223
-
-
Rodig, S.J.1
Mino-Kenudson, M.2
Dacic, S.3
Yeap, B.Y.4
Shaw, A.5
Barletta, J.A.6
|